CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 46 enrolled
Drug / intervention
Full-Spectrum Cannabidiol +2 moredrug
Likely dose
Full-Spectrum Cannabidiol 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02548559
NCT02548559Phase 2Completed
CompareCT.gov

Sublingual Cannabidiol for Anxiety

Staci Gruber, Ph.D.·interventional·Posted Sep 14, 2015·Updated Mar 27, 2026

In Brief

A Phase 2 clinical trial evaluating Full-Spectrum Cannabidiol, Single-Compound Cannabidiol, and 1 other intervention for Anxiety. Completed, enrolled 46 participants across 1 site.

Detailed Summary

This is an open-label to double-blind study evaluating the effects of cannabidiol (CBD) for the treatment of anxiety in adults. Participants will use a sublingual (under-the-tongue) solution of whole plant-derived CBD or placebo three times daily for four weeks in addition to their normal treatment regimen. Participants' clinical state will be assessed weekly during the treatment period. In addition, cognitive function and measures of quality of life, sleep, and general health will be assessed at baseline and the post-treatment final visit.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnxiety
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 14, 2015
Enrollment StartAug 14, 2018
Primary CompletionMar 13, 2025
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 10.8 years ago

Interventions

Full-Spectrum Cannabidioldrug

Full-Spectrum Cannabidiol; total daily dose of 30 mg.

Single-Compound Cannabidioldrug

Single-Compound Cannabidiol; total daily dose of 30 mg.

Placebodrug

Placebo solution.